Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 22 Jul 2024 21:08:47 +0200Thu, 02 May 2024 15:14:00 +0200Human medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/byoovizHuman medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/byoovizThu, 02 May 2024 15:14:00 +0200Human medicineByooviz : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5545-en_1.pdfByooviz : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5545-en_1.pdfThu, 02 May 2024 13:22:00 +0200Human medicine